Share This Article:

Successful Treatment of Elderly Diffuse Large B-Cell Lymphoma with Central Nervous System Recurrence by Rituximab, Ranimusutine, Ifosfamide, Procarbazine, Dexamethasone, and Etoposide Therapy

Full-Text HTML Download Download as PDF (Size:194KB) PP. 448-451
DOI: 10.4236/jct.2013.43A054    3,245 Downloads   5,326 Views  

ABSTRACT

The prognosis of CD20-positive (CD20+) diffuse large B-cell lymphoma (DLBCL) with central nervous system (CNS) recurrence is still poor. A standard treatment for CD20+ DLBCL with CNS recurrence in elderly patients has not been established mainly due to adverse effects. We previously reported the efficacy and safety of MIND-E (ranimustine, ifosfamide, procarbazine, dexamethasone, and etoposide) therapy for elderly CD20+ DLBCL patients with CNS recurrence. Here, we report the use of R-MIND-E therapy (rituximab, ranimustine, ifosfamide, procarbazine, dexamethasone and etoposide) in an elderly CD20+ DLBCL patient with CNS recurrence. The patient achieved a complete response according to Revised Response Criteria for Malignant Lymphoma, and treatment-related toxicity was tolerable. R-MIND-E therapy may be a feasible and useful treatment option for elderly CD20+ DLBCL patients with CNS recurrence.

Cite this paper

J. Miyahara, N. Takezako, M. Wagatsuma, K. Midorikawa, I. Fukuda, S. Noto, I. Saito, K. Yamada, A. Miwa and N. Sekiguchi, "Successful Treatment of Elderly Diffuse Large B-Cell Lymphoma with Central Nervous System Recurrence by Rituximab, Ranimusutine, Ifosfamide, Procarbazine, Dexamethasone, and Etoposide Therapy," Journal of Cancer Therapy, Vol. 4 No. 3A, 2013, pp. 448-451. doi: 10.4236/jct.2013.43A054.

References

[1] B. Coiffier, E. Lepage, J. Briere, et al., “CHOP Chemotherapy Plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large B Cell Lymphoma,” New England Journal of Medicine, Vol. 346, No. 4, 2002, pp. 235-242. doi:10.1056/NEJMoa011795
[2] W. M. Tai, J. Chung, P. L. Tang, et al., “Central Nervous System (CNS) Relapse in Diffuse Large B Cell Lymphoma (DLBCL): Preand Post-Rituximab,” Annals of Hematology, Vol. 90, No. 7, 2011, pp. 809-818. doi:10.1007/s00277-010-1150-7
[3] A. Miwa, N. Sekiguchi, A. Tanimura, et al., “Ranimustine, Ifosfamide, Procarbazine, Dexamethasone, and Etoposide Therapy for Central Nervous System Recurrence of Diffuse Large B-Cell Lymphoma in Patients with Poor Performance Status: A Pilot Study,” Leukemia and Lymphoma, Vol. 52, No. 10, 2011, pp. 1898-1903. doi:10.3109/10428194.2011.588759
[4] G. D. Shah, J. Yahalom, D. D. Correa, et al., “Combined Immunochemotherapy with Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma,” Journal of Clinical Oncology, Vol. 25, No. 30, 2007, pp. 4730-4735. doi:10.1200/JCO.2007.12.5062
[5] R. C. Curry, D. Correa, J. J. Raizer, et al., “Consolidation Reduced Dose Whole Brain Radiotherapy (rdWBRT) Following Methotrexate, Rituximab, Procarbazine, Vincristine, Cytarabine (R-MPV-A) for Newly Diagnosed Primary CNS Lymphoma (PCNSL): Final Results and Long-Term Outcome,” Journal of Clinical Oncology, Vol. 30, No. 15, 2012, p. 2006.
[6] T. Bimbaum, E. A. Stadler, L. V. Baumgarten and A. Straube, “Rituximab Significantly Improves Complete Response Rate in Patients with Primary CNS Lymphoma,” Journal of Neurooncology, Vol. 109, No. 2, 2012, pp. 285-291. doi:10.1007/s11060-012-0891-7
[7] M. J. Wieduwilt, F. Valles, S. Issa, et al., “Immunochemotherapy with Intensive Consolidation for Primary CNS Lymphoma: A Pilot Study and Prognostic Assessment by Diffusion-Weighted MRI,” Clincal Cancer Research, Vol. 18, No. 4, 2012, pp. 1146-1155. doi:10.1158/1078-0432.CCR-11-0625
[8] B. D. Cheson, B. Pfistner, M. E. Juweid, et al., “Revised Response Criteria for Malignant Lymphoma,” Journal of Clinical Oncology, Vol. 25, No. 5, 2007, pp. 579-586. doi:10.1200/JCO.2006.09.2403
[9] D. Villa, J. M. Connors, T. N. Shenkier, et al., “Incidence and Risk Factors for Central Nervous System Relapse in Patients with Diffuse Large B-Cell Lymphoma: The Impact of the Addition of Rituximab to CHOP Chemotherapy,” Annals of Oncology, Vol. 21, No. 5, 2010, pp. 1046-1052. doi:10.1093/annonc/mdp432
[10] P. Feugier, J. M. Virion, H. Tilly, et al., “Incidence and Risk Factors for Central Nervous System Occurrence in Elderly Patients with Diffuse Large-B-Cell Lymphoma: Influence of Rituximab,” Annals of Oncology, Vol. 15, No. 1, 2004, pp. 129-133. doi:10.1093/annonc/mdh013
[11] Y. Shimizu, K. Notohara, and Y. Ueda, “Diffuse Large B-Cell Lymphoma with Central Nervous System Relapse: Prognosis and Risk Factors According to Retrospective Analysis from a Single-Center Experience,” International Journal of Hematology, Vol. 89, No. 5, 2009, pp. 577-583. doi:10.1007/s12185-009-0289-2
[12] R. Kridel and P. Dietrich, “Prevention of CNS Relapse in Diff Use Large B-Cell Lymphoma,” The Lancet Oncology, Vol. 12, No. 13, 2011, pp. 1258-1266. doi:10.1016/S1470-2045(11)70140-1
[13] A. Harjunpaa, T. Wiklund, J. Collan, et al., “Complement Activation in Circulation and Central Nervous System after Rituximab (Anti-CD20) Treatment of B-Cell Lymphoma,” Leukemia and Lymphoma, Vol. 42, No. 4, 2001, pp. 731-738. doi:10.3109/10428190109099335
[14] S. J. Kim, S. Y. Oh, J. S. Kim, et al., “Secondary Central Nervous System (CNS) Involvement in Patients with Diffuse Large B-Cell Lymphoma: A Therapeutic Dilemma,” Annals of Hematology, Vol. 90, No. 5, 2011, pp. 539-546. doi:10.1007/s00277-010-1104-0
[15] A. Kumar, A Vanderplas, A. S. LaCasce, et al., “Lack of Benefit of Central Nervous System Prophylaxis for Diffuse Large B-Cell Lymphoma in the Rituximab Era,” Cancer, Vol. 118, No. 11, 2012, pp. 2944-2951. doi:10.1002/cncr.26588
[16] N. Schmitz, S. Zeynalova, M. Loeffler, et al., “Response: Intrathecal Methotrexate and Central Nervous System Events,” Blood, Vol. 114, No. 9, 2009, pp. 1999-2000. doi:10.1182/blood-2009-06-226076
[17] J. S. Abramson, M. Hellmann, J. A. Barnes, et al., “Intravenous Methotrexate as Central Nervous System (CNS) Prophylaxis Is Associated with a Low Risk of CNS Recurrence in High-Risk Patients with Diffuse Large B-Cell Lymphoma,” Cancer, Vol. 116, No. 18, 2010, pp. 4283-4290. doi:10.1002/cncr.25278
[18] Q. A. Hill and R. G. Owen, “CNS Prophylaxis in Lymphoma: Who to Target and What Therapy to Use,” Blood Reviews, Vol. 20, No. 6, 2006, pp. 319-332. doi:10.1016/j.blre.2006.02.001
[19] N. D. Doolittle, L. E. Abrey, T. N. Shenkier, et al., “Brain Parenchyma Involvement as Isolated Central Nervous system Relapse of Systemic Non-Hodgkin Lymphoma an International Primary CNS Lymphoma Collaborative Group Report,” Blood, Vol. 111, No. 3, 2008, pp. 1085-1093. doi:10.1182/blood-2007-07-101402
[20] A. M. P. Omuro, L. M. DeAngelis, Yahalom J, et al., “Chemoradiotherapy for Primary CNS Lymphoma an Intent-to-Treat Analysis with Complete Follow-Up,” Neurology, Vol. 64, No. 1, 2005, pp. 69-74. doi:10.1212/01.WNL.0000148641.98241.5E

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.